AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share

PRESS RELEASEAB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHAREParis, December ...
Yahoo Finance

AB Science will participate in the Biomed Forum investors conference

AB Science SA (Euronext – FR0010557264 – AB) announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors. Organized by ...
Yahoo Finance

AB Science will publish its 2024 annual financial report on May 9, 2025

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time ...

AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040

PRESS RELEASEAB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION ...
manilatimes

AB Science today provides an update on its masitinib platform

AB Science SA (Euronext - FR0010557264 - AB) today provides an update on its masitinib platform. The webcast presentation is available on the company's website, in ...
Pharmabiz

AB Science receives US patent for masitinib to treat sickle cell disease

AB Science receives US patent for masitinib to treat sickle cell disease: Paris Friday, December 26, 2025, 14:00 Hrs [IST] AB Science SA, a pharmaceutical company specializing in ...
TipRanks on MSN

AB Science granted U.S. patnet for masitinib in treatment of SCD

AB Science (ABSCF) announced that the United States Patent Office has formally granted a patent for methods of treating sickle cell disease using ...
Morningstar

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are ...
FierceBiotech

AB Science trumpets phase 3 ALS data, but investors seem unmoved

After years of disappointment, things might seem to be looking up for the amyotrophic lateral sclerosis patient community. Two weeks ago they got a new drug approved by the FDA, and now French biotech ...
FierceBiotech

Analysts lay into AB Science after regulatory misstep

Analysts have torn into AB Science over the clinical trial compliance failings identified by regulators in France. Oddo took the most extreme action by slashing its price target from €48 ($53) to €5, ...
Morningstar

AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML

AB Science SA (Euronext - FR0010557264 - AB) today announced the approval of the third of four stages of the Phase I/II study (AB18001) with the compound AB8939 in adult patients with ...
Taiwan News

AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function

AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of a new article on the preprint platform MedRxiv, presenting a post-hoc subgroup analysis of the phase 2b/3 AB10015 study ...